BR112017021586A2 - Uso de (4-hidróxi-2-metil-1,1-dióxido-2h-benzo-[e][1,2] tiazin-3-il)(naftalen-2-il) metanona na prevenção e/ou no tratamento de esteato-hepatite não alcoólica - Google Patents
Uso de (4-hidróxi-2-metil-1,1-dióxido-2h-benzo-[e][1,2] tiazin-3-il)(naftalen-2-il) metanona na prevenção e/ou no tratamento de esteato-hepatite não alcoólicaInfo
- Publication number
- BR112017021586A2 BR112017021586A2 BR112017021586-1A BR112017021586A BR112017021586A2 BR 112017021586 A2 BR112017021586 A2 BR 112017021586A2 BR 112017021586 A BR112017021586 A BR 112017021586A BR 112017021586 A2 BR112017021586 A2 BR 112017021586A2
- Authority
- BR
- Brazil
- Prior art keywords
- methanone
- benzo
- hydroxy
- dioxide
- prevention
- Prior art date
Links
- 230000002265 prevention Effects 0.000 title abstract 2
- 230000001476 alcoholic effect Effects 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 title 1
- PJKVFARRVXDXAD-UHFFFAOYSA-N 2-naphthaldehyde Chemical compound C1=CC=CC2=CC(C=O)=CC=C21 PJKVFARRVXDXAD-UHFFFAOYSA-N 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- -1 [1,2] thiazin-3-yl Chemical group 0.000 abstract 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1553574A FR3035326B1 (fr) | 2015-04-21 | 2015-04-21 | Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphtalen-2-yl)methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique |
| FR1553574 | 2015-04-21 | ||
| PCT/EP2016/058760 WO2016169983A1 (fr) | 2015-04-21 | 2016-04-20 | Utilisation de la (4-hydroxy-2-methyl-1,1-dioxido-2h-benzo[e][1,2]thiazin-3-yl)(naphthalen-2-yl) methanone dans la prevention et/ou le traitement de la steatohepatite non-alcoolique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017021586A2 true BR112017021586A2 (pt) | 2018-07-03 |
Family
ID=53484018
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017021586-1A BR112017021586A2 (pt) | 2015-04-21 | 2016-04-20 | Uso de (4-hidróxi-2-metil-1,1-dióxido-2h-benzo-[e][1,2] tiazin-3-il)(naftalen-2-il) metanona na prevenção e/ou no tratamento de esteato-hepatite não alcoólica |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20180140609A1 (enExample) |
| EP (1) | EP3285774B1 (enExample) |
| JP (1) | JP2018513175A (enExample) |
| KR (1) | KR20170139030A (enExample) |
| CN (1) | CN107530355A (enExample) |
| AU (1) | AU2016251601A1 (enExample) |
| BR (1) | BR112017021586A2 (enExample) |
| CA (1) | CA2981933A1 (enExample) |
| FR (1) | FR3035326B1 (enExample) |
| MX (1) | MX2017013453A (enExample) |
| RU (1) | RU2017137262A (enExample) |
| WO (1) | WO2016169983A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102177304B1 (ko) | 2018-07-23 | 2020-11-10 | 제이투에이치바이오텍 (주) | 비알콜성 지방간염의 예방 또는 치료용 약학 조성물 |
| RU2706026C1 (ru) * | 2018-12-28 | 2019-11-13 | Государственное бюджетное учреждение здравоохранения города Москвы Московский клинический научно-практический центр им. А.С. Логинова Департамента здравоохранения города Москвы | Способ лечения неалкогольной жировой болезни печени и сахарного диабета второго типа |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0107383D0 (en) * | 2001-03-23 | 2001-05-16 | Univ Edinburgh | Lipid profile modulation |
| JP2007197369A (ja) * | 2006-01-26 | 2007-08-09 | Sankyo Co Ltd | ベンゾチアジン誘導体 |
| FR2942797B1 (fr) * | 2009-03-03 | 2011-04-29 | Pf Medicament | Derives de benzothiazines, leur preparation et leur application a titre de medicaments |
| KR101134447B1 (ko) * | 2009-11-30 | 2012-04-10 | 에스케이 주식회사 | 아세트아마이드기를 갖는 사이클릭설폰아미드 유도체, 이의 제조방법 및 이를 함유하는 약학 조성물 |
| JP2011213685A (ja) * | 2010-04-01 | 2011-10-27 | Kowa Co | ベンゾイミダゾリルピペリジン誘導体を有効成分とする１１β−ヒドロキシステロイドデヒドロゲナーゼ１阻害剤 |
| ES2543692T3 (es) * | 2010-04-29 | 2015-08-21 | The University Of Edinburgh | (8-aza-biciclo[3.2.1biciclo[oct-8-il)-[5-(1H-pirazol-4-il)-tiofeno-3-il]-metanonas 3,3-disustituidas como inhibidores de 11beta-HSD1 |
| ES2617215T3 (es) * | 2011-04-19 | 2017-06-15 | Daiichi Sankyo Company, Limited | Derivado de tetrahirotiazepina |
-
2015
- 2015-04-21 FR FR1553574A patent/FR3035326B1/fr not_active Expired - Fee Related
-
2016
- 2016-04-20 CA CA2981933A patent/CA2981933A1/fr not_active Abandoned
- 2016-04-20 EP EP16717911.8A patent/EP3285774B1/fr active Active
- 2016-04-20 WO PCT/EP2016/058760 patent/WO2016169983A1/fr not_active Ceased
- 2016-04-20 MX MX2017013453A patent/MX2017013453A/es unknown
- 2016-04-20 RU RU2017137262A patent/RU2017137262A/ru not_active Application Discontinuation
- 2016-04-20 KR KR1020177030299A patent/KR20170139030A/ko not_active Withdrawn
- 2016-04-20 JP JP2017555239A patent/JP2018513175A/ja active Pending
- 2016-04-20 BR BR112017021586-1A patent/BR112017021586A2/pt not_active Application Discontinuation
- 2016-04-20 US US15/568,085 patent/US20180140609A1/en not_active Abandoned
- 2016-04-20 AU AU2016251601A patent/AU2016251601A1/en not_active Abandoned
- 2016-04-20 CN CN201680023190.6A patent/CN107530355A/zh active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| FR3035326B1 (fr) | 2017-05-12 |
| EP3285774A1 (fr) | 2018-02-28 |
| CA2981933A1 (fr) | 2016-10-27 |
| WO2016169983A1 (fr) | 2016-10-27 |
| AU2016251601A1 (en) | 2017-11-30 |
| RU2017137262A3 (enExample) | 2019-09-30 |
| US20180140609A1 (en) | 2018-05-24 |
| KR20170139030A (ko) | 2017-12-18 |
| CN107530355A (zh) | 2018-01-02 |
| FR3035326A1 (fr) | 2016-10-28 |
| EP3285774B1 (fr) | 2020-01-08 |
| JP2018513175A (ja) | 2018-05-24 |
| RU2017137262A (ru) | 2019-05-21 |
| MX2017013453A (es) | 2017-12-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016009337A (es) | Derivados de azepano y metodos para tratar infecciones por hepatitis b. | |
| BR112015020466A8 (pt) | inibidores de cdc7, seus usos, e composição farmacêutica | |
| BR112015024411A2 (pt) | desaza-purinonas macrocíclicas para o tratamento de infeções virais | |
| BR112015011036A2 (pt) | derivados de 2-amino-quinazolina substituídos heterocíclicos para o tratamento de infecções virais | |
| MX2012011222A (es) | Compuestos y composiciones farmaceuticas para el tratamiento de infecciones virales. | |
| NZ702744A (en) | D-amino acid compounds for liver disease | |
| BR112015020118A2 (pt) | derivados de 2-aminopirimidina para o tratamento de infecções virais | |
| BR112018077457A2 (pt) | composição farmacêutica para evitar ou tratar hiperinsulinismo congênito e seu método, hipoglicemia e seu método, síndrome metabólica e seu método e peptídeo isolado | |
| BR112018005904A2 (pt) | composto, e, método de prevenção e/ou tratamento do hiv. | |
| BR112018015718A2 (pt) | utilização de estimuladores de sgc para o tratamento de esteato-hepatite não alcoólica (nash) | |
| BR112016016853A2 (pt) | Compostos contendo nitrogênio, seu uso e seu processo de preparação, composição farmacêutica e seu uso | |
| MX2016014731A (es) | Tratamiento de las complicaciones de la enfermedad cronica del higado con enfermedades de caspasa. | |
| BR112018005870A2 (pt) | composto, e, método de prevenção e/ou tratamento do hiv. | |
| MX2016008397A (es) | Composicion para usarse en el tratamiento de tos persistente. | |
| EA201790726A1 (ru) | Фармацевтическая композиция для лечения язвенного колита | |
| BR112017020796A2 (pt) | compostos, composição farmacêutica e kit | |
| BR112017004580A2 (pt) | composto, composição farmacêutica, produto de combinação, uso de um composto ou sal farmaceuticamente aceitável, e, método de tratamento. | |
| WO2017040407A8 (en) | Compositions and methods for the reduction or prevention of non-alcoholic steatohepatitis (nash) | |
| BR112015016033A8 (pt) | composições farmacêuticas para tratamento de infecções por bactérias, e seus usos | |
| BR112017005272A2 (pt) | uso de cisteamina no tratamento de infecções causadas por leveduras/bolores | |
| BR112017021586A2 (pt) | Uso de (4-hidróxi-2-metil-1,1-dióxido-2h-benzo-[e][1,2] tiazin-3-il)(naftalen-2-il) metanona na prevenção e/ou no tratamento de esteato-hepatite não alcoólica | |
| MX2016000037A (es) | Inhibidores de replicacion viral, su proceso de preparacion y sus usos terapeuticos. | |
| MX382439B (es) | Compuestos de carbapenem | |
| PH12017500820A1 (en) | Combination long acting compositions and methods for hepatitis c | |
| PH12017500816A1 (en) | Long acting pharmaceutical compositions for hepatitis c |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notice of approval relating to section 229 industrial property law | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: suspension of the patent application procedure | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |